Quoin Pharmaceuticals (QNRX) Non-Current Assets (2017 - 2026)
Quoin Pharmaceuticals (QNRX) posted Non-Current Assets of $358334.0 for Q1 2026, down 6.52% sequentially from $383334.0 in Q4 2025, and down 21.82% YoY from $458334.0 in Q1 2025.
Quoin Pharmaceuticals (QNRX) Non-Current Assets (2017 - 2026) Analysis & Trends
Quoin Pharmaceuticals has reported Non-Current Assets for 10 years, with the latest figure at $358334.0 in Q1 2026.
- Quarterly Non-Current Assets fell 21.82% year-over-year to $358334.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 46.63% YoY) and the FY2025 annual result came in at $383334.0, down 51.06% from the prior year.
- Non-Current Assets retreated to $358334.0 in Q1 2026 per QNRX's latest filing, from $383334.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.1 million in Q4 2022 and troughed at $358334.0 in Q1 2026.
- A 5-year average of $749452.1 and a median of $819958.5 in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets gained 28.43% in 2023, then slumped 54.21% in 2025.
- Over 5 years, Non-Current Assets stood at $1.1 million in 2022, then declined by 18.81% to $883334.0 in 2023, then declined by 11.32% to $783334.0 in 2024, then tumbled by 51.06% to $383334.0 in 2025, then retreated by 6.52% to $358334.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $358334.0, $383334.0, and $408334.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Quoin Pharmaceuticals | 491,038.58 | 491,038.58 | - | 333,334.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 358,334.00 |
| Dec 31, 2025 | 383,334.00 |
| Sep 30, 2025 | 408,334.00 |
| Jun 30, 2025 | 433,334.00 |
| Mar 31, 2025 | 458,334.00 |
| Dec 31, 2024 | 783,334.00 |
| Sep 30, 2024 | 891,724.00 |
| Jun 30, 2024 | 833,334.00 |
| Mar 31, 2024 | 858,334.00 |
| Dec 31, 2023 | 883,334.00 |
| Sep 30, 2023 | 926,529.00 |
| Jun 30, 2023 | 1.04 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 780,572.00 |
| Jun 30, 2022 | 806,583.00 |
| Dec 31, 2021 | 1.16 Mn |
| Dec 31, 2020 | 912,648.00 |
| Jun 30, 2020 | 693,000.00 |
| Jun 30, 2019 | 902,000.00 |